156 recruiting, 135 completed, 88 terminated, 79 unknown. 604 Phase 2, 175 Phase 1, 9 Phase 3.
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | The University of The West Indies | 750 | 2027-06-01 | 2026-09-22 |
| A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | Phase 2 | Recruiting | Medical University of South Carolina | 55 | 2027-01-01 | 2026-10-15 |
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BLEX 404 Oral Liquid - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 44 | 2027-01-01 | 2026-04-13 |
| Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer Cromolyn, TQB2102, and Panpulimab - Triple -Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 46 | 2027-01-01 | 2026-09-25 |
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-11-05 | 2026-05-28 |
| Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer Pembrolizumab - Early Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 84 | 2026-11-01 | 2026-10-05 |
| A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 60 | 2026-11-01 | 2026-10-16 |
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies CRG-150 - HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | CoRegen, Inc. | 67 | 2026-11-01 | 2026-10-02 |
| A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC) JS212 in combination with JS207, JS212 monotherapy, JS212 in combination with JS001 - Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 184 | 2026-10-15 | 2026-10-15 |
| Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer LVB infiltration - Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | Institut Jean-Godinot | 760 | 2026-10-01 | 2026-03-09 |
| Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Zn-Telomir - Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Telomir Pharmaceuticals, Inc. | 76 | 2026-10-01 | 2026-06-23 |
| Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC Pembrolizumab, Paclitaxel (Chemotherapy), Carboplatin - Triple-Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-10-01 | 2026-08-26 |
| US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 32 | 2026-10-01 | 2026-10-07 |
| Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC Group 1-Isunakinra - Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-10-01 | 2026-10-22 |
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2026-09-15 | 2026-06-24 |
| Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC Carboplatin, Docetaxel, Doxorubicin - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 110 | 2026-09-01 | 2026-08-04 |
| Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer Sacituzumab Govitecan / Trastuzumab Deruxtecan - Triple Negative Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Not yet recruiting | UNICANCER | 260 | 2026-09-01 | 2026-08-03 |
| A Study of IOV-5001 in Adults With Advanced Solid Tumors IOV-5001 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Iovance Biotherapeutics, Inc. | 106 | 2026-09-01 | 2026-09-15 |
| Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer Live biotherapeutic product: MO-03 1 capsule PO BID - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Yuan Yuan | 50 | 2026-09-01 | 2026-08-05 |
Showing 20 of 604. Sign in to see all of them.
Breast Neoplasms (243) · Carcinoma, Non-Small-Cell Lung (71) · Neoplasm Metastasis (46) · Ovarian Neoplasms (45) · Squamous Cell Carcinoma of Head and Neck (41) · Melanoma (36) · Colorectal Neoplasms (31) · Carcinoma, Renal Cell (30) · Stomach Neoplasms (29) · Neoplasms (26) · Endometrial Neoplasms (25) · Uterine Cervical Neoplasms (24) · Small Cell Lung Carcinoma (22) · Pancreatic Neoplasms (21)
Skin Diseases (604) · Skin and Connective Tissue Diseases (604) · Breast Diseases (603) · Neoplasms by Site (603) · Neoplasms (578) · Breast Neoplasms (361) · Neoplasms by Histologic Type (98) · Neoplasms, Glandular and Epithelial (85) · Respiratory Tract Neoplasms (84) · Urogenital Diseases (84) · Urogenital Neoplasms (84) · Female Urogenital Diseases (83) · Female Urogenital Diseases and Pregnancy Complications (83) · Lung Diseases (83) · Respiratory Tract Diseases (83)
Carboplatin (103) · pembrolizumab (100) · Paclitaxel (82) · Cyclophosphamide (62) · Capecitabine (43) · 130-nm albumin-bound paclitaxel (39) · Doxorubicin (36) · Gemcitabine (31) · Albumin-Bound Paclitaxel (30) · Taxes (30) · Cisplatin (29) · Bevacizumab (24) · sacituzumab govitecan (24) · atezolizumab (23) · Epirubicin (22)
Fudan University (42) · M.D. Anderson Cancer Center (15) · National Cancer Institute (NCI) (15) · Sun Yat-sen University (8) · Tianjin Medical University Cancer Institute and Hospital (8) · Gilead Sciences (7) · Memorial Sloan Kettering Cancer Center (7) · AstraZeneca (6) · Chinese Academy of Medical Sciences (6) · Novartis Pharmaceuticals (6) · Vanderbilt-Ingram Cancer Center (6) · Bristol-Myers Squibb (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · Dana-Farber Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (5)
United States (296) · China (146) · Spain (58) · France (46) · United Kingdom (41) · Canada (39) · Italy (35) · Australia (31) · Belgium (29) · South Korea (29) · Germany (24) · Japan (20) · Taiwan (20) · Poland (16) · Netherlands (14)
Kari Wisinski, MD (5) · Priyanka Sharma, MD (5) · Clinton Yam (4) · David Page, MD (3) · Soo Chin Lee (3) · Yuan Yuan, MD (3) · Zhenzhen Liu (3) · Zhimin Shao, Professor (3)
PMID 25092775, PMID 19299237, PMID 24529560, PMID 27872127, PMID 30345906, PMID 32101663, PMID 32966830, PMID 34173924, PMID 35728046, PMID 39302614, PMID 16011702, PMID 16077072, PMID 17438091, PMID 17641361, PMID 18258986, PMID 19097774, PMID 19487376, PMID 20157582, PMID 20304629, PMID 20404251, PMID 20586616, PMID 21208101, PMID 21383283, PMID 21633166, PMID 21796368, PMID 21862407, PMID 21865043, PMID 22198468, PMID 22323820, PMID 22415477, PMID 22623692, PMID 22649152, PMID 23430121, PMID 23810467, PMID 23922302, PMID 24292957, PMID 24399079, PMID 24583822, PMID 24824628, PMID 25218906, PMID 25349301, PMID 25585328, PMID 25589624, PMID 25648299, PMID 25847929, PMID 25915780, PMID 25944802, PMID 26006067, PMID 26056183, PMID 26059540
2023 (13), 2018 (10), 2016 (9), 2017 (9), 2019 (7), P30CA068485 (4), UM1CA186704 (4), 2014 (3), 2025 (3), UM1CA186689 (3), 2015 (2), P30CA006516 (2), P30CA060553 (2), P30CA072720 (2), P30CA138292 (2)